Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ChemoCentryx
Biotech
AdComm experts split on whether to OK ChemoCentryx's avacopan
Ten experts voted that the benefit-risk profile supports approval, while the other eight voted against authorizing the rare disease drug.
Nick Paul Taylor
May 7, 2021 6:47am
ChemoCentryx's stock sinks as FDA flags issues with pivotal data
May 5, 2021 8:25am
ChemoCentryx pulls conditional approval filing
Jan 24, 2019 9:40am
ChemoCentryx eyes combinations after posting pancreatic cancer OS data
Jan 23, 2018 8:05am
Vifor flies solo, plans spending spree as sister unit files IPO
Apr 7, 2017 2:38am
$85M windfall for PhIII licensing deal sparks a rally for ChemoCentryx
May 11, 2016 7:39am
